NAVAMEDIC (NAVA.OL) Stock Fundamental Analysis

Europe • Euronext Oslo • OSL:NAVA • NO0010205966

22.1 NOK
-0.3 (-1.34%)
Last: Feb 6, 2026, 07:00 PM
Fundamental Rating

2

NAVA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 55 industry peers in the Pharmaceuticals industry. NAVA may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, NAVA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • NAVA had negative earnings in the past year.
  • NAVA had a positive operating cash flow in the past year.
  • In multiple years NAVA reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: NAVA reported negative operating cash flow in multiple years.
NAVA.OL Yearly Net Income VS EBIT VS OCF VS FCFNAVA.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

  • The Return On Assets of NAVA (-5.53%) is worse than 72.73% of its industry peers.
  • NAVA has a worse Return On Equity (-18.80%) than 76.36% of its industry peers.
  • The Return On Invested Capital of NAVA (2.25%) is worse than 67.27% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for NAVA is below the industry average of 14.23%.
  • The last Return On Invested Capital (2.25%) for NAVA is well below the 3 year average (10.14%), which needs to be investigated, but indicates that NAVA had better years and this may not be a problem.
Industry RankSector Rank
ROA -5.53%
ROE -18.8%
ROIC 2.25%
ROA(3y)1.27%
ROA(5y)-0.47%
ROE(3y)1.61%
ROE(5y)-1.5%
ROIC(3y)10.14%
ROIC(5y)N/A
NAVA.OL Yearly ROA, ROE, ROICNAVA.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

1.3 Margins

  • The Operating Margin of NAVA (2.99%) is worse than 70.91% of its industry peers.
  • NAVA's Operating Margin has improved in the last couple of years.
  • With a Gross Margin value of 37.32%, NAVA is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
  • In the last couple of years the Gross Margin of NAVA has grown nicely.
Industry RankSector Rank
OM 2.99%
PM (TTM) N/A
GM 37.32%
OM growth 3Y13.14%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y5.2%
NAVA.OL Yearly Profit, Operating, Gross MarginsNAVA.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), NAVA is creating some value.
  • NAVA has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for NAVA has been increased compared to 5 years ago.
  • NAVA has a better debt/assets ratio than last year.
NAVA.OL Yearly Shares OutstandingNAVA.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
NAVA.OL Yearly Total Debt VS Total AssetsNAVA.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • NAVA has a debt to FCF ratio of 27.52. This is a negative value and a sign of low solvency as NAVA would need 27.52 years to pay back of all of its debts.
  • NAVA has a worse Debt to FCF ratio (27.52) than 67.27% of its industry peers.
  • A Debt/Equity ratio of 1.34 is on the high side and indicates that NAVA has dependencies on debt financing.
  • NAVA has a Debt to Equity ratio of 1.34. This is in the lower half of the industry: NAVA underperforms 74.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF 27.52
Altman-Z N/A
ROIC/WACC0.27
WACC8.2%
NAVA.OL Yearly LT Debt VS Equity VS FCFNAVA.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 1.49 indicates that NAVA should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.49, NAVA perfoms like the industry average, outperforming 56.36% of the companies in the same industry.
  • NAVA has a Quick Ratio of 1.49. This is a bad value and indicates that NAVA is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.77, NAVA is doing worse than 70.91% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.49
Quick Ratio 0.77
NAVA.OL Yearly Current Assets VS Current LiabilitesNAVA.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • NAVA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -290.46%.
  • NAVA shows a small growth in Revenue. In the last year, the Revenue has grown by 2.64%.
  • The Revenue has been growing by 23.00% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-290.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-194.12%
Revenue 1Y (TTM)2.64%
Revenue growth 3Y24.05%
Revenue growth 5Y23%
Sales Q2Q%12.89%

3.2 Future

  • NAVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.39% yearly.
  • NAVA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.79% yearly.
EPS Next Y-144.15%
EPS Next 2Y-24.66%
EPS Next 3Y10.9%
EPS Next 5Y31.39%
Revenue Next Year10.54%
Revenue Next 2Y18.87%
Revenue Next 3Y17.55%
Revenue Next 5Y12.79%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NAVA.OL Yearly Revenue VS EstimatesNAVA.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
NAVA.OL Yearly EPS VS EstimatesNAVA.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • NAVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 30.09 indicates a quite expensive valuation of NAVA.
  • NAVA's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. NAVA is more expensive than 67.27% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 27.78. NAVA is around the same levels.
Industry RankSector Rank
PE N/A
Fwd PE 30.09
NAVA.OL Price Earnings VS Forward Price EarningsNAVA.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as NAVA.
  • NAVA's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. NAVA is more expensive than 60.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 46.79
EV/EBITDA 13.83
NAVA.OL Per share dataNAVA.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.66%
EPS Next 3Y10.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for NAVA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NAVAMEDIC

OSL:NAVA (2/6/2026, 7:00:00 PM)

22.1

-0.3 (-1.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-30
Earnings (Next)N/A
Inst Owners30.47%
Inst Owner ChangeN/A
Ins Owners12.02%
Ins Owner ChangeN/A
Market Cap529.96M
Revenue(TTM)539.42M
Net Income(TTM)-39.43M
Analysts82.86
Price Target36.72 (66.15%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.04%
Min Revenue beat(2)-7.18%
Max Revenue beat(2)-4.89%
Revenue beat(4)0
Avg Revenue beat(4)-4.82%
Min Revenue beat(4)-7.18%
Max Revenue beat(4)-1.92%
Revenue beat(8)1
Avg Revenue beat(8)-6.44%
Revenue beat(12)4
Avg Revenue beat(12)-1.99%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-10%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-300%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 30.09
P/S 0.98
P/FCF 46.79
P/OCF 36.17
P/B 2.53
P/tB N/A
EV/EBITDA 13.83
EPS(TTM)-2.21
EYN/A
EPS(NY)0.73
Fwd EY3.32%
FCF(TTM)0.47
FCFY2.14%
OCF(TTM)0.61
OCFY2.76%
SpS22.49
BVpS8.74
TBVpS-10.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.53%
ROE -18.8%
ROCE 2.92%
ROIC 2.25%
ROICexc 2.52%
ROICexgc 42.03%
OM 2.99%
PM (TTM) N/A
GM 37.32%
FCFM 2.1%
ROA(3y)1.27%
ROA(5y)-0.47%
ROE(3y)1.61%
ROE(5y)-1.5%
ROIC(3y)10.14%
ROIC(5y)N/A
ROICexc(3y)12.6%
ROICexc(5y)N/A
ROICexgc(3y)98.8%
ROICexgc(5y)N/A
ROCE(3y)13.17%
ROCE(5y)N/A
ROICexgc growth 3Y90.11%
ROICexgc growth 5YN/A
ROICexc growth 3Y12.82%
ROICexc growth 5YN/A
OM growth 3Y13.14%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y5.2%
F-Score2
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF 27.52
Debt/EBITDA 4.97
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 25.95%
Profit Quality N/A
Current Ratio 1.49
Quick Ratio 0.77
Altman-Z N/A
F-Score2
WACC8.2%
ROIC/WACC0.27
Cap/Depr(3y)19.25%
Cap/Depr(5y)40.99%
Cap/Sales(3y)0.55%
Cap/Sales(5y)0.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-290.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-194.12%
EPS Next Y-144.15%
EPS Next 2Y-24.66%
EPS Next 3Y10.9%
EPS Next 5Y31.39%
Revenue 1Y (TTM)2.64%
Revenue growth 3Y24.05%
Revenue growth 5Y23%
Sales Q2Q%12.89%
Revenue Next Year10.54%
Revenue Next 2Y18.87%
Revenue Next 3Y17.55%
Revenue Next 5Y12.79%
EBIT growth 1Y-59.15%
EBIT growth 3Y40.35%
EBIT growth 5YN/A
EBIT Next Year15.84%
EBIT Next 3Y37.82%
EBIT Next 5Y26.96%
FCF growth 1Y-75.72%
FCF growth 3YN/A
FCF growth 5Y24.61%
OCF growth 1Y-69.13%
OCF growth 3YN/A
OCF growth 5Y25.36%

NAVAMEDIC / NAVA.OL FAQ

Can you provide the ChartMill fundamental rating for NAVAMEDIC?

ChartMill assigns a fundamental rating of 2 / 10 to NAVA.OL.


Can you provide the valuation status for NAVAMEDIC?

ChartMill assigns a valuation rating of 1 / 10 to NAVAMEDIC (NAVA.OL). This can be considered as Overvalued.


What is the profitability of NAVA stock?

NAVAMEDIC (NAVA.OL) has a profitability rating of 2 / 10.